| Species |
Mouse |
| Protein Construction |
| Avi |
His |
TNFSF15 (Ala61-Leu252)_x000D_
Accession # Q5UBV8 |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized TNFSF15, His & Avi, Mouse at 1μg/ml (100μl/well) on the plate can bind AntiTNFSF15 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
24.40 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 30-38 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
TL1A and its functional receptor DR3 are members of the TNF/TNFR superfamilies of proteins.TL1A and DR3 are abundantly localized at inflamed intestinal areas of patients with IBD and mice with experimental ileitis or colitis and actively participate in the immunological pathways that underlie mucosal homeostasis and intestinal inflammation.Recently, an important role was demonstrated for TL1A/DR3 as potential mediators of intestinal fibrosis that is associated with the presence of gut inflammation. |
| Synonyms |
TL1A; VEGI-251; TNFSF15; TL1; VEGI; VEGI192A |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
